These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

115 related articles for article (PubMed ID: 35058596)

  • 1. Outcomes based on treatment setting in refractory acute myeloid leukemia and other high-grade myeloid malignancies.
    Kopmar NE; Othus M; Gardner KM; Shaw C; Halpern AB; Scott BL; Hendrie PC; Walter RB; Becker PS; Estey EH; Percival MM
    Leukemia; 2022 Apr; 36(4):1164-1166. PubMed ID: 35058596
    [No Abstract]   [Full Text] [Related]  

  • 2. Twice-daily fludarabine and cytarabine combination with or without gentuzumab ozogamicin is effective in patients with relapsed/refractory acute myeloid leukemia, high-risk myelodysplastic syndrome, and blast- phase chronic myeloid leukemia.
    Jabbour E; Garcia-Manero G; Cortes J; Ravandi F; Plunkett W; Gandhi V; Faderl S; O'Brien S; Borthakur G; Kadia T; Burger J; Konopleva M; Brandt M; Huang X; Kantarjian H
    Clin Lymphoma Myeloma Leuk; 2012 Aug; 12(4):244-51. PubMed ID: 22534616
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Activity of the oral mitogen-activated protein kinase kinase inhibitor trametinib in RAS-mutant relapsed or refractory myeloid malignancies.
    Borthakur G; Popplewell L; Boyiadzis M; Foran J; Platzbecker U; Vey N; Walter RB; Olin R; Raza A; Giagounidis A; Al-Kali A; Jabbour E; Kadia T; Garcia-Manero G; Bauman JW; Wu Y; Liu Y; Schramek D; Cox DS; Wissel P; Kantarjian H
    Cancer; 2016 Jun; 122(12):1871-9. PubMed ID: 26990290
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Targeting Hedgehog pathway in pediatric acute myeloid leukemia: challenges and opportunities.
    Pession A; Lonetti A; Bertuccio S; Locatelli F; Masetti R
    Expert Opin Ther Targets; 2019 Feb; 23(2):87-91. PubMed ID: 30556755
    [No Abstract]   [Full Text] [Related]  

  • 5. Empiric definition of eligibility criteria for clinical trials in relapsed/refractory acute myeloid leukemia: analysis of 1,892 patients from HOVON/SAKK and SWOG.
    Walter RB; Othus M; Löwenberg B; Ossenkoppele GJ; Petersdorf SH; Pabst T; Vekemans MC; Appelbaum FR; Erba HP; Estey EH
    Haematologica; 2015 Oct; 100(10):e409-11. PubMed ID: 26160876
    [No Abstract]   [Full Text] [Related]  

  • 6. Three hematologic malignancies in the same patient: chronic lymphocytic leukemia, followed by chronic myeloid leukemia and acute myeloid leukemia.
    Fattizzo B; Radice T; Cattaneo D; Pomati M; Barcellini W; Iurlo A
    Clin Lab; 2014; 60(11):1929-32. PubMed ID: 25648037
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Pathogenic and therapeutic roles of cytokines in acute myeloid leukemia.
    Karimdadi Sariani O; Eghbalpour S; Kazemi E; Rafiei Buzhani K; Zaker F
    Cytokine; 2021 Jun; 142():155508. PubMed ID: 33810945
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The safety and efficacy of vosaroxin in patients with first relapsed or refractory acute myeloid leukemia - a critical review.
    Short NJ; Ravandi F
    Expert Rev Hematol; 2016 Jun; 9(6):529-34. PubMed ID: 27158854
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Murine double minute 2 inhibition alone or with cytarabine in acute myeloid leukemia: Results from an idasanutlin phase 1/1b study⋆.
    Yee K; Papayannidis C; Vey N; Dickinson MJ; Kelly KR; Assouline S; Kasner M; Seiter K; Drummond MW; Yoon SS; Lee JH; Blotner S; Jukofsky L; Pierceall WE; Zhi J; Simon S; Higgins B; Nichols G; Monnet A; Muehlbauer S; Ott M; Chen LC; Martinelli G
    Leuk Res; 2021 Jan; 100():106489. PubMed ID: 33302031
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Phase I/II trial of cladribine, high-dose cytarabine, mitoxantrone, and G-CSF with dose-escalated mitoxantrone for relapsed/refractory acute myeloid leukemia and other high-grade myeloid neoplasms.
    Halpern AB; Othus M; Huebner EM; Scott BL; Hendrie PC; Percival MM; Becker PS; Smith HA; Oehler VG; Orozco JJ; Cassaday RD; Gardner KM; Chen TL; Buckley SA; Orlowski KF; Anwar A; Estey EH; Walter RB
    Haematologica; 2019 Apr; 104(4):e143-e146. PubMed ID: 30409798
    [No Abstract]   [Full Text] [Related]  

  • 11. A phase I study of carfilzomib for relapsed or refractory acute myeloid and acute lymphoblastic leukemia.
    Wartman LD; Fiala MA; Fletcher T; Hawkins ER; Cashen A; DiPersio JF; Jacoby MA; Stockerl-Goldstein KE; Pusic I; Uy GL; Westervelt P; Vij R
    Leuk Lymphoma; 2016; 57(3):728-30. PubMed ID: 26674111
    [No Abstract]   [Full Text] [Related]  

  • 12. [Effects of FLAG regimen in treatment of refractory or relapsed acute myeloid leukemia].
    Wu XX; Da WM; Li HH; Zhao Y; Wang QS; Wang SH; Zhu HY
    Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2005 Jun; 13(3):394-6. PubMed ID: 15972128
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Idarubicin in the treatment of relapsed or refractory acute myeloid leukemia.
    Harousseau JL; Hurteloup P; Reiffers J; Rigal-Huguet F; Hayat M; Dufour P; Le Prise PY; Monconduit M; Jaubert J; Carcassonne Y
    Cancer Treat Rep; 1987 Oct; 71(10):991-2. PubMed ID: 3477319
    [No Abstract]   [Full Text] [Related]  

  • 14. Novel strategies for relapsed and refractory acute myeloid leukemia.
    Mato AR; Morgans A; Luger SM
    Curr Opin Hematol; 2008 Mar; 15(2):108-14. PubMed ID: 18300756
    [TBL] [Abstract][Full Text] [Related]  

  • 15. BCR-ABL1(+) acute myeloid leukemia: clonal selection of a BCR-ABL1(-) subclone as a cause of refractory disease with nilotinib treatment.
    Neuendorff NR; Schwarz M; Hemmati P; Türkmen S; Bommer C; Burmeister T; Dörken B; le Coutre P; Arnold R; Westermann J
    Acta Haematol; 2015; 133(2):237-41. PubMed ID: 25401297
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Fludarabine-treosulfan compared to thiotepa-busulfan-fludarabine or FLAMSA as conditioning regimen for patients with primary refractory or relapsed acute myeloid leukemia: a study from the Acute Leukemia Working Party of the European Society for Blood and Marrow Transplantation (EBMT).
    Saraceni F; Labopin M; Brecht A; Kröger N; Eder M; Tischer J; Labussière-Wallet H; Einsele H; Beelen D; Bunjes D; Niederwieser D; Bochtler T; Savani BN; Mohty M; Nagler A
    J Hematol Oncol; 2019 Apr; 12(1):44. PubMed ID: 31023346
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Recent progress in the treatment of hematological malignancies. II. Chemotherapy of relapsed and refractory acute myeloid leukemia in adult].
    Ohshima T
    Nihon Naika Gakkai Zasshi; 1989 Jun; 78(6):774-80. PubMed ID: 2794659
    [No Abstract]   [Full Text] [Related]  

  • 18. Phase I/II study of the hypoxia-activated prodrug PR104 in refractory/relapsed acute myeloid leukemia and acute lymphoblastic leukemia.
    Konopleva M; Thall PF; Yi CA; Borthakur G; Coveler A; Bueso-Ramos C; Benito J; Konoplev S; Gu Y; Ravandi F; Jabbour E; Faderl S; Thomas D; Cortes J; Kadia T; Kornblau S; Daver N; Pemmaraju N; Nguyen HQ; Feliu J; Lu H; Wei C; Wilson WR; Melink TJ; Gutheil JC; Andreeff M; Estey EH; Kantarjian H
    Haematologica; 2015 Jul; 100(7):927-34. PubMed ID: 25682597
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Updates on Hematologic Malignancies in the Older Adult: Focus on Acute Myeloid Leukemia, Chronic Lymphocytic Leukemia, and Multiple Myeloma.
    Huang LW; Wong SW; Andreadis C; Olin RL
    Curr Oncol Rep; 2019 Mar; 21(4):35. PubMed ID: 30848394
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Precision medicine for acute myeloid leukemia.
    Lai C; Karp JE; Hourigan CS
    Expert Rev Hematol; 2016 Jan; 9(1):1-3. PubMed ID: 26514194
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.